VIGONVITA-B (02630)
Vigonvita Life Sciences Co., Ltd., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for neuropsychiatry, reproductive health, and viral infection therapeutic areas. Its lead products include LV232, a first-in-class dual-target serotonin transporter/5-hydroxytryptamine 3 receptor modulators, which is in Phase II of clinical trial for the treatm
CS Hotline: +852 3018 4526
Trading days: 24 hours | Non-trading days: 9:00-18:00
